

Iressa® (gefitinib) – First-time generic

- On May 3, 2023, Ingenus launched an <u>AB-rated</u> generic version of AstraZeneca's <u>Iressa (gefitinib)</u> tablets.
 - <u>Apotex</u> and <u>Actavis/Teva</u> received FDA approval of AB-rated generic versions of Iressa on September 23, 2022 and April 26, 2023, respectively. Launch plans for these two generics are pending.
- Iressa is approved for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.